Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia

Journal of Psychopharmacology

Volumn 11, Issue 1, 1997, Pages 3-12

  Busatto, G F ^a   Kerwin, R W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

5 HT2 receptors; Atypical antipsychotics; Clozapine; Extrapyramidal side effects; Risperidone; Serotonin

Indexed keywords

NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; GENETIC SUSCEPTIBILITY; HUMAN; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

ANIMALS; AUTONOMIC PATHWAYS; HUMANS; RATS; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0030909322     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119701100102     Document Type: Review

References (127)

1. 2A receptors. J Nucl Med 36: 164P
2. Akbarian S, Kim J J, Potkin S G, Hagman J O, Tafazzoli A, Bunney W E, Jr, Jones E G (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Archs Gen Psychiat 52: 258-266
3. 2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull 16: 517-525
4. 2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm Gen Sect 85: 19-29
5. 2A receptor gene. Lancet 346: 281-282
6. 2 receptors in the medial prefrontal cortex: microiontophoretic studies. Brain Res 506: 346-348
7. Azmitia E C, Whitaker-Azmitia P M (1991) Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. J Clin Psychiat 52 (Suppl. 12): 4-16
8. Beasley C M, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S and the Olanzapine HGAD Study Group (1996) Olanzapine versus placebo and haloperidol - acute phase results of the North American double-blind olanzepine trial. Neuropsychopharmacology 14: 111-123
9. A receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 12: 924-929
10. 2 antagonist ritanserin in neuroleptic-induced Parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmac 13: 500-506
11. Bleich A, Brown S L, Kahn R, van Praag H M (1988) The role of serotonin in schizophrenia. Schizophr Bull 14: 297-315
12. 2 receptors and serotonergic axons in rat neocortex. Brain Res 453: 315-328
13. Bobker D H, Williams J T (1990) Serotonin-mediated inhibitory post-synaptic potential in guinea-pig prepositus hypoglossi and feedback inhibition by serotonin. J Physiol Lond 422: 447-462
14. Bradley P B, Engel G, Feniuk W, Fozard J R, Humphrey P P, Middlemiss D N, Mylecharane E J, Richardson B P, Saxena P R (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25: 563-576
15. Breier A (1995) Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 14: 187-202
16. Breier A, Kirkpatrick B, Buchanan R W (1993) Clozapine attenuates meta-chlorophenylpiperazine (m-CPP)-induced plasma cortisol increases in schizophrenia. Biol Psychiat 34: 492-494
17. 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology 117: 55-61
18. Busatto G F, Pilowsky L S, Costa D C, Ell P J, David A S, Kerwin R W (1996) Reduced benzodiazepine receptor binding correlates with severity of psychotic symptoms in schizophrenia. Am J Psychiat, in press
19. 1C sites. Europ J Pharmac 191: 93-96
20. Carter C J, Pycock C J (1977) Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats. Br J Pharmac 60: 267P-268P
21. Casey D E (1993) Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology 112 (Suppl. 1): S55-S59
22. Chiang C, Aston Jones G (1993) Response of locus coeruleus neurons to footshock stimulation is mediated by neurons in the rostral ventral medulla. Neuroscience 53: 705-715
23. Chouinard G, Jones B, Remington G et al. (1993) Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmac 13: 25-40
24. 3 receptor antagonists. Int Clin Psychopharmac 8 (Suppl. 2): 3-9
25. Costall B, Fortune D H, Naylor R J, Mardsen C D, Pycock C (1975) Serotoninergic involvement with neuroleptic catalepsy. Neuropharmacology 14: 859-868
26. 3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmac 92: 881-894
27. 3 receptor antagonists attenuate dopamine-induced hyperactivity in the rat. Neuroreport 1: 77-80
28. Cowen P (1991) Serotonin receptor subtypes: implications for psychopharmacology. Br J Psychiat 159 (Suppl. 12): 7-14
29. Crow T J (1980) Molecular pathology of schizophrenia: More than one disease process? BMJ 280: 66-68
30. Curtis V A, Wright P, Reveley A, Kerwin R, Lucey J V (1995) Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. Br J Psychiat 166: 642-646
31. 1C receptors. Trends Pharmac Sci 11: 181-182
32. Davis K L, Kahn R S, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiat 148: 1474-1486
33. Deakin J F (1991) Depression and 5-HT. Int Clin Psychopharmac 6 (Suppl. 3): 23-28
34. Deutch A Y, Moghaddam B, Innis R B, Krystal J H, Aghajanian G K, Bunney B S, Charney D S (1991) Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4: 121-156
35. Dewey S L, Smith G S, Logan J, Alexoff D, DingY S, King P, Pappas N, Brodie J D, Ashby C R J (1995) Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15: 821-829
36. Dubovsky S L, Thomas M (1995) Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiat 56 (Suppl. 2): 38-48
37. 2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiat 163: 451-455
38. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archs Gen Psychiat 49: 538-544
39. 2-receptor occupancy in clozapine-treated patients. J Clin Psychiat 55 (Suppl. B): 67-69
40. 2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmac 15: 19S-23S
41. Fibiger H, Miller J (1977) An anatomical and electrophysiologic investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the cat. Neuroscience 2: 975-987
42. Gelders Y G (1989) Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiat 155 (Suppl. 5): 33-36
43. Gellman R L, Aghajanian G K (1994) Serotonin 2 receptor-mediated excitation of interneurons in piriform cortex: antagonism by atypical antipsychotic drugs. Neuroscience 58: 515-525
44. Glennon R A, Dukat M (1991) Serotonin receptors and their ligands: a lack of selective agents. Pharmac Biochem Behav 40: 1009-1017
45. Goldman-Rakic P S, Lidow M S, Gallager D W (1990) Overlap of dopaminergic, adrenergic, and serotonergic receptors and complementarity of their subtypes in primate prefrontal cortex. J Neurosci 10: 2125-2138
46. 7 receptor in rat brain. Br J Pharmac 117: 657-666
47. Hervé D, Simon H, Blane G, LeMoal M, Glowinski J, Tassin J P (1981) Opposite changes in dopamine utilization in the nucleus accumbens and the frontal cortex after electrolytic lesions of the median raphe in the rat. Brain Res 216: 422-428
48. Hervé D, Pickel V M, Joh T H, Beaudet A (1987) Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res 435: 71-83
49. Hicks P B (1990) The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 47: 1609-1615
50. 3 recognition sites: fact or artifact? Eur J Pharmac 171: 137-139
51. 1D receptors. Ann N Y Acad Sci 600: 168-181
52. Hoyer D, Clarke D E, Fozard J R, Hartig P R, Martin G R, Mylecharane E J, Saxena P R, Humphrey P P (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmac Rev 46: 157-203
53. Ichikawa J, Meltzer H Y (1995) Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmac 281: 255-261
54. Iqbal N, Asnis G M, Wetzler S, Kahn R, Kay S R, van Praag H M (1991) The MCPP challenge test in schizophrenia: hormonal and behavioural responses. Biol Psychiat 30: 770-778
55. Jenner P, Sheehy M, Marsden C D (1983) Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. Br J Clin Pharmac 15 (Suppl. 2): 277S-289S
56. Kahn R S, Davidson M, Siever L, Gabriel S, Apter S, Davis K L (1993) Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiat 150: 1337-1342
57. Kane J, Honingfeld G, Stuger J et al. (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archs Gen Psychiat 45: 789-796
58. Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiat 153: 466-476
59. Kerwin R W (1994) The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiat 164: 141-148
60. 3 receptors in rat brain using radioligand binding. Nature 330: 746-748
61. Krystal J H, Seibyl J P, Price L H, Woods S W, Heninger G R, Aghajanian G K, Charney D S (1993) m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Archs Gen Psychiat 50: 624-635
62. 2C). Genomics 27: 274-279
63. Laruelle M, Abi-Dargham A, Casanova M F, Toti R, Weinberger D R, Kleinman J E (1993) Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Archs Gen Psychiat 50: 810-818
64. Leysen J E, Niemegeers C J E, Tollenaere J P, Laduron P M (1978) Serotonergic component of neuroleptic receptors. Nature 272: 168
65. 2 receptors. Psychopharmacology 112 (Suppl.): S40-S54
66. Leysen J E, Janssen P M, Megens A A, Schotte A (1994) Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiat 55 (Suppl.): 5-12
67. Link C G C, Arvanitis L, on behalf of the US Seroquel™ Group (1995) Seroquel treatment of hospitalized patients with acute exacerbation of chronic and subchronic schizophrenia. A multicentre, placebo-controlled, double-blind study. Eur Neuropsychopharmac 5: 346
68. 1E-like rat and human 5-hydroxytryptamine receptor genes. Proc Natl Acad Sci USA 90: 2184-2188
69. Lucas J J, Hen R (1996) New players in the 5-HT receptor field: genes and knockouts. Trends Pharmac Sci 16: 246-252
70. Marder S R, Meibach R C (1994) Risperidone in the treatment of schizophrenia. Am J Psychiat 151: 825-835
71. 1A receptors in human brain tissue. Eur J Pharmac 227: 397-398
72. McBain S L, Dineen M, Weller M, Taylor S, Cooksey P, Williams P, Corn T (1992) Ondansetron, a double-blind placebo-controlled study in acute schizophrenia. Schizophr Res 6: 112
73. Meltzer H Y (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 35: S18-S27
74. Meltzer H Y (1991) Studies of ondansetron in schizophrenia. Biol Psychiat 2: 891-893
75. Meltzer H Y (1993) New drugs for the treatment of schizophrenia. Psychiat Clin N Am 16: 365-385
76. Meltzer H Y (1994) An overview of the mechanism of action of clozapine. J Clin Psychiat 55 (Suppl. B): 47-52
77. Meltzer HY, Bastani B, Kwon K Y, Ramirez L F, Burnett S, Sharpe J A (1989a) A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology 99 (Suppl.): S68-S72
78. 2 pKi values. J Pharmac Exp Therap 251: 238-246
79. 2 antagonist ritanserin. Psychopharmac Bull 26: 373-376
80. Moghaddam B, Bunney B S (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from préfrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54: 1755-1760
81. Monferini E, Gaetani P, Rodriguez B, Giraldo E, Parenti M, Zocchetti A, Rizzi C A (1993) Pharmacological characterization of the 5-hydroxytryptamine receptor coupled to adenylyl cyclase stimulation in human brain. Life Sci 52: PL61-PL65
82. Monsma F J, Shen Y, Ward R P, Hamblin M W, Sibley D R (1993) Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Molec Pharmac 43: 587-604
83. Nash J F, Meltzer H G, Gudelsky G H (1988) Antagonism of serotonin receptor-mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. Eur J Pharmac 191: 463-469
84. Newcomer J W, Faustman W O, Zipursky R B, Csernansky J G (1992) Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial. Archs Gen Psychiat 49: 751-752
85. Nomikos G G, Zis A P, Iumo M, Andersson J L (1994) Systematic administration of amperozide, a new atypical antipsychotic drug, preferentially depresses dopamine release in the rat medial frontal cortex. Psychopharmacology 115: 147-156
86. 2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double blind PET study of schizophrenic patients. Biol Psychiat 33: 227-235
87. 2 receptors to decrease potassium conductance in rat nucleus accumbens neurones. J Physiol Lond 417: 1-12
88. 1 receptors. Neuroscience 21: 97-122
89. 2 receptors. Neuroscience 21: 123-139
90. Peroutka S J (1994) Molecular biology of serotonin (5-HT) receptors. Synapse 18: 241-260
91. Peroutka S J, Snyder S H (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiat 137: 1518-1522
92. 3 receptors. Trends Pharmac Sci 13: 391-397
93. Pickar D, Owen R R, Litman R E, Konicki E, Gutierrez R, Rapaport M H (1992) Clinical and biologic response to clozapine in patients with schizophrenia: cross-over comparison with fluphenazine. Archs Gen Psychiat 49: 345-353
94. Pierce P A, Peroutka S J (1989) Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology 97: 118-122
95. 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340: 199-202
96. 2 dopamine receptor blockade and clinical response: a 1231 IBZM SPET (single photon emission tomography) study. Psychol Med 23: 791-797
97. 2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 1231 IBZM single photon emission tomography (SPET) study. Psychopharmacology 124: 148-153
98. 2C receptors. Brain Res Molec Brain Res 23: 163-178
99. Potkin S G, Weinberger D R, Linnoila M, Wyatt R J (1983) Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles. Am J Psychiat 140: 21-25
100. 1C receptors. J Pharmac Exp Therap 260: 1361-1365
101. Roth B L, Craigo S C, Choudhary M S, Uluer A, Monsma F J, Jr., Shen Y, Meltzer HY, Sibley D R (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmac Exp Therap 268: 1403-1410
102. 18F]altanserin: results in young normal controls. J Cereb Blood Flow Metab 15: 787-797
103. 2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiat Scand 90: 266-268
104. Schotte A, Janssen P F M, Gommeren W, Luyten W H M L, Van Gompel P, Lesage AS, DeLoore K, Leysen J E (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124: 57-73
105. Seeman P (1990) Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiat Scand 358 (Suppl.): 14-20
106. Seeman P, Lee T, Chau Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717-719
107. Sharp T, Bramwell S R, Hjorth S, Grahame Smith D G (1989) Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis. Br J Pharmac 98: 989-997
108. 2 receptors in interneurons. Synapse 9: 208-218
109. Sleight A J, Carolo C, Petit N, Zwingelstein C, Bourson A (1995) Identification of 5-hydroxytryptamine 7 receptor binding sites in rat hypothalamus: Sensitivity to chronic antidepressant treatment. Molec Pharmac 47: 99-103
110. 2C receptor gene. Neuroreport 7: 169-172
111. Stephenson J D (1990) Neuropharmacological studies of the serotonergic system. Int Rev Psychiat 2: 157-178
112. Stocklin G (1992) Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology. Eur J Nucl Med 19: 527-551
113. Stockmeier C A, DiCarlo J J, Zhang Y, Thompson P, Meltzer H Y (1993) Characterization of typical and atypical antipsychotic drugs basend on in vivo occupancy of serotonin 2 and dopamine 2 receptors. J Pharmac Exp Therap 266: 1374-1384
114. Targum S, Zborowski J, Henry M, Schmitz P, Sebree T, Wallin B (1995) Efficacy and safety of sertindole in two double-blind, placebo-controlled trials of schizophrenic patients. Eur Neuropsychopharmac 5: 348
115. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45-50
116. van Kammen D P, McEvoy J P, Targum S D, Kardatzke D, Sebree T B, Sertindole Study Group (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 116: 168-175
117. Waldmeier P C, Delini-Stula A A (1979) Serotonin-dopamine interactions in the nigro-striatal system. Eur J Pharmac 55: 363-373
118. 3-like receptors in the action of clozapine. J Clin Psychiat 55 (Suppl. B): 23-26
119. 3 receptors in the cerebral cortex and superior cervical ganglion of the rat. Eur J Pharmac 182: 465-472
120. Weinberger D R (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Archs Gen Psychiat 44: 660-669
121. White A, Corn T H, Feetham C, Faulconbridge C (1991) Ondansetron in treatment of schizophrenia. Lancet 337: 1173
122. Wiesel F A, Nordstrom A L, Farde L, Eriksson B (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 114: 31-38
123. Williams J, Spurlock G, McGuffin P, Mallet J, Nothen M M, Gill M, Aschauer H, Nylander P-O, Macciardi F, Owen M J for the European Multicentre Association Study of Schizophrenia (1996) Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. Lancet 347: 1294-1296
124. Wilson M A, Molliver M E (1991) The organization of serotonergic projections to cerebral cortex in primates: regional distribution of axon terminals. Neuroscience 44: 537-553
125. 2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology 100: 417-425
126. Wooley DW, Shaw E (1954) A biological and pharmacological suggestion about certain mental disorders. Proc Nat Acad Sci USA 40: 228-231
127. Yamamoto B K, Pehek E A, Meltzer H Y (1994) Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiat 55 (Suppl. B): 8-14